Skip to main content

Advances in Therapy for Chronic Lymphocytic Leukemia

51kviews
CASE REPORT
21 April 2023
Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
Ester Lovato, 3 more and Isacco Ferrarini

2,937 views

3 citations

ORIGINAL RESEARCH
11 April 2023
Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo
David E. Spaner, 4 more and Yonghong Shi

3,401 views

8 citations

REVIEW
22 February 2023
The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials
A. Fisher, 3 more and T. Munir

5,834 views

11 citations

REVIEW
4 January 2023
Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
Zong-Han Wang, 2 more and Fujun Han
Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) has become one of the most common hematological diseases in western countries, with an annual incidence of 42/100,000. Conventional chemotherapy and targeted therapeutic drugs showed limitations in prognosis or in efficiency in high-risk patients. Immunotherapy represented is one of the most effective therapeutic approaches with the potential of better effect and prognosis. Natural killer (NK) cells are good options for immunotherapy as they can effectively mediate anti-tumor activity of immune system by expressing activating and inhibiting receptors and recognizing specific ligands on various tumor cells. NK cells are critical in the immunotherapy of CLL by enhancing self-mediated antibody-dependent cytotoxicity (ADCC), allogeneic NK cell therapy and chimeric antigen receptor-natural killer (CAR-NK) cell therapy. In this article, we reviewed the features, working mechanisms, and receptors of NK cells, and the available evidence of the advantages and disadvantages of NK cell-based immunotherapies, and put forward future study directions in this field.

4,421 views

15 citations